Truist Securities Reiterates Regeneron Pharma (REGN) at Buy, NTLA-2001 is an Underappreciated Opportunity with Significant Upside
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $728.00 price target on Regeneron Pharma (NASDAQ: REGN), following a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
